- Home
- KFS vs ABEO Comparison
KFS vs ABEO Comparison
Compare KFS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- ABEO
- Stock Information
- Founded
- KFS 1989
- ABEO N/A
- Country
- KFS United States
- ABEO United States
- Employees
- KFS N/A
- ABEO N/A
- Industry
- KFS Property-Casualty Insurers
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- ABEO Health Care
- Exchange
- KFS Nasdaq
- ABEO Nasdaq
- Market Cap
- KFS 234.2M
- ABEO 277.6M
- IPO Year
- KFS 1996
- ABEO 1980
- Fundamental
- Price
- KFS $8.94
- ABEO $5.86
- Analyst Decision
- KFS
- ABEO Strong Buy
- Analyst Count
- KFS 0
- ABEO 3
- Target Price
- KFS N/A
- ABEO $18.00
- AVG Volume (30 Days)
- KFS 31.2K
- ABEO 292.3K
- Earning Date
- KFS 11-06-2024
- ABEO 11-14-2024
- Dividend Yield
- KFS N/A
- ABEO N/A
- EPS Growth
- KFS N/A
- ABEO N/A
- EPS
- KFS N/A
- ABEO N/A
- Revenue
- KFS $108,627,000.00
- ABEO N/A
- Revenue This Year
- KFS N/A
- ABEO N/A
- Revenue Next Year
- KFS N/A
- ABEO $7,097.06
- P/E Ratio
- KFS N/A
- ABEO N/A
- Revenue Growth
- KFS 2.02
- ABEO 147.52
- 52 Week Low
- KFS $6.85
- ABEO $3.05
- 52 Week High
- KFS $9.58
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- KFS 50.02
- ABEO 38.62
- Support Level
- KFS $8.70
- ABEO $5.95
- Resistance Level
- KFS $9.00
- ABEO $6.78
- Average True Range (ATR)
- KFS 0.30
- ABEO 0.32
- MACD
- KFS -0.08
- ABEO -0.07
- Stochastic Oscillator
- KFS 31.18
- ABEO 7.07
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.